Gayatri Bioorganics revises FY26 audited results for typos
Gayatri Bioorganics Limited submitted revised audited financial results for the quarter and year ended March 31, 2026, to rectify typographical errors, stating there was no impact on financial performance. The company reported a net loss of ₹111.18 lakh for FY26, with total expenses rising to ₹111.18 lakh and revenue remaining nil. The statutory auditor issued an unmodified opinion on the results.
*this image is generated using AI for illustrative purposes only.
Gayatri Bioorganics Limited submitted revised audited financial results for the quarter and year ended March 31, 2026, due to typographical errors identified in the previously submitted data. The company clarified that these corrections have no impact on its financial performance, profitability, cash flows, or any other material financial information. The Board of Directors approved the revised results at a meeting held on May 19, 2026.
Financial Performance
The company reported a net loss of ₹111.18 lakh for the financial year ended March 31, 2026, widening from a net loss of ₹72.65 lakh in the previous year. Revenue from operations remained nil for both the quarter and the full year under review. Total expenses for the year rose to ₹111.18 lakh from ₹72.65 lakh in the prior year, primarily driven by higher finance costs and other expenses. Employee benefit expenses increased to ₹11.29 lakh from ₹8.50 lakh, finance costs rose to ₹35.77 lakh from ₹27.68 lakh, and other expenses climbed to ₹64.12 lakh from ₹36.47 lakh.
For the quarter ended March 31, 2026, the net loss stood at ₹42.05 lakh, compared to ₹17.46 lakh in the corresponding quarter of the previous year. Basic and diluted earnings per share for the year stood at ₹(0.14), against ₹(0.09) in the prior year.
The following table summarizes the key financial metrics for the year and quarter ended March 31, 2026:
| Particulars: | Q4 FY26 (₹ in Lakhs) | Q3 FY26 (₹ in Lakhs) | Q4 FY25 (₹ in Lakhs) | FY26 (₹ in Lakhs) | FY25 (₹ in Lakhs) |
|---|---|---|---|---|---|
| Revenue from Operations | - | - | - | - | - |
| Employee Benefits Expenses | 2.22 | 2.55 | 2.12 | 11.29 | 8.50 |
| Finance Cost | 9.74 | 9.44 | 7.41 | 35.77 | 27.68 |
| Other Expenses | 30.09 | 9.72 | 7.93 | 64.12 | 36.47 |
| Total Expenses | 42.05 | 21.71 | 17.46 | 111.18 | 72.65 |
| Net Profit/(Loss) | (42.05) | (21.71) | (17.46) | (111.18) | (72.65) |
| Basic/Diluted EPS (₹) | (0.05) | (0.03) | (0.02) | (0.14) | (0.09) |
Balance Sheet Highlights
As at March 31, 2026, the company's total assets stood at ₹171.75 lakh, compared to ₹166.35 lakh in the previous year. Equity share capital remained unchanged at ₹7,878.81 lakh, while other equity deteriorated to ₹(11,579.31) lakh from ₹(11,468.12) lakh, resulting in a negative net worth of ₹(3,700.49) lakh. Non-current borrowings increased significantly to ₹3,523.14 lakh from ₹349.73 lakh, while current borrowings declined to ₹174.40 lakh from ₹3,340.35 lakh.
| Particulars: | March 31, 2026 (₹ in Lakhs) | March 31, 2025 (₹ in Lakhs) |
|---|---|---|
| Total Assets | 171.75 | 166.35 |
| Equity Share Capital | 7,878.81 | 7,878.81 |
| Other Equity | (11,579.31) | (11,468.12) |
| Net Worth | (3,700.49) | (3,589.31) |
| Non-Current Borrowings | 3,523.14 | 349.73 |
| Current Borrowings | 174.40 | 3,340.35 |
| Trade Receivables | 25.36 | 25.36 |
| Cash and Cash Equivalents | 68.02 | 2.04 |
Cash Flow Summary
Net cash used in operating activities for the year was ₹(7.51) lakh, compared to ₹(55.06) lakh in the prior year. There were no cash flows from investing activities. Cash flow from financing activities amounted to ₹73.50 lakh, primarily from proceeds of short-term borrowings. As a result, cash and cash equivalents at the end of the year stood at ₹68.02 lakh, compared to ₹2.04 lakh at the end of the previous year.
Auditor's Report
The statutory auditor, M/s. MGR & Co., Chartered Accountants (Firm Registration Number: 012787S), issued an unmodified opinion on the standalone financial results for the quarter and year ended March 31, 2026. The auditors confirmed that the financial statements give a true and fair view of the company's financial position. The financial statements have been prepared on a going concern basis, supported by a comfort letter provided by the promoters of the company.
Historical Stock Returns for Gayatri Bioorganics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.90% | -20.35% | -54.25% | -30.71% | +17.02% | -15.73% |
Given Gayatri Bioorganics has reported zero revenue for multiple consecutive years with a deeply negative net worth, what specific turnaround strategy or business revival plan does the management intend to execute to restore operational activity?
How long can the promoters continue providing comfort letters to support the going concern assumption, and what are the conditions or milestones that could trigger a withdrawal of this support?
With non-current borrowings surging from ₹349.73 lakh to ₹3,523.14 lakh, what are the terms, interest rates, and repayment schedules of these restructured debt obligations, and how will the company service them without any revenue?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
